Assignee
SPECTRUM PHARMACEUTICALS INC
US·27 granted patents·25 pending applications·163 citations·filing 2001–2025
Top patents by PatentIndex Score
52 records- 0192US8026216B2Methods and compositions for contributing to the treatment of cancersSPECTRUM PHARMACEUTICALS INC·Filed 2008·Granted Sep 27, 2011·8 cites·11 claims
- 0291US10350240B2Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and useSPECTRUM PHARMACEUTICALS INC·Filed 2013·Granted Jul 16, 2019·27 cites·20 claims
- 0390US8349802B2Methods and compositions for contributing to the treatment of cancersSPECTRUM PHARMACEUTICALS INC·Filed 2011·Granted Jan 8, 2013·6 cites·11 claims
- 0490US6894071B2Medical compositions for intravesical treatment of bladder cancerSPECTRUM PHARMACEUTICALS INC·Filed 2002·Granted May 17, 2005·42 cites·10 claims
- 0589US6770638B2Tetrahydroindolone and purine derivatives linked to arylpiperazinesSPECTRUM PHARMACEUTICALS INC·Filed 2002·Granted Aug 3, 2004·22 cites·12 claims
- 0687US8030278B2Methods, compositions and articles of manufacture for contributing to the treatment of cancersSPECTRUM PHARMACEUTICALS INC·Filed 2009·Granted Oct 4, 2011·7 cites·16 claims
- 0786US6759427B2Synthesis and methods of use of tetrahydroindolone analogues and derivativesSPECTRUM PHARMACEUTICALS INC·Filed 2001·Granted Jul 6, 2004·16 cites·2 claims
- 0885US6982269B2Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivativesSPECTRUM PHARMACEUTICALS INC·Filed 2002·Granted Jan 3, 2006·16 cites·17 claims
- 0983US11267858B2Methods of treatment using G-CSF protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2019·Granted Mar 8, 2022·2 cites·21 claims
- 1083US7977369B2Medical compositions for intravesical treatment of bladder cancerSPECTRUM PHARMACEUTICALS INC·Filed 2008·Granted Jul 12, 2011·6 cites·14 claims
- 1182US9308235B2Treatment of primary and metastatic carcinomaSPECTRUM PHARMACEUTICALS INC·Filed 2013·Granted Apr 12, 2016·3 cites·17 claims
- 1281US12350315B2Methods of treating neutorpenia using G-CSF protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2023·Granted Jul 8, 2025·0 cites·13 claims
- 1381US8377456B2Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivativesSPECTRUM PHARMACEUTICALS INC·Filed 2011·Granted Feb 19, 2013·3 cites·26 claims
- 1481US2026000733A1Novel methods of treating neutorpenia using g-csf protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1580US12318430B2Methods of treating neutorpenia using G-CSF protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2023·Granted Jun 3, 2025·0 cites·15 claims
- 1679US2025197466A1Methods of treatment using g-csf protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1778US9295666B2Bladder cancer treatment and methodsSPECTRUM PHARMACEUTICALS INC·Filed 2013·Granted Mar 29, 2016·1 cites·12 claims
- 1878US8852543B2Rare earth metal compounds, methods of making, and methods of using the sameSPECTRUM PHARMACEUTICALS INC·Filed 2014·Granted Oct 7, 2014·2 cites·7 claims
- 1977US2025367257A1Methods of treating neutorpenia using g-csf protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2075US11439643B2Combination therapy using belinostat and pralatrexate to treat lymphomaSPECTRUM PHARMACEUTICALS INC·Filed 2016·Granted Sep 13, 2022·1 cites·5 claims
- 2174US12202871B2Methods of treatment using G-CSF protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2022·Granted Jan 21, 2025·0 cites·20 claims
- 2273US8734818B2Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivativesSPECTRUM PHARMACEUTICALS INC·Filed 2013·Granted May 27, 2014·1 cites·26 claims
- 2371US2023106731A1Inhibitors of mutant family tyrosine-kinasesSPECTRUM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2468US11684655B2Methods of treating neutorpenia using G-CSF protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2020·Granted Jun 27, 2023·0 cites·22 claims
- 2568US2025121032A1Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2664US2009076123A1Medical Compositions for Intravesical Treatment of Bladder CancerSPECTRUM PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2763US2014288143A1Bladder cancer treatment and methodsSPECTRUM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2863US2015004086A1Rare earth metal compounds, methods of making, and methods of using the sameSPECTRUM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2961US12171804B2Methods of treating chemotherapy induced neutropenia using fixed doses of eflapegrastimSPECTRUM PHARMACEUTICALS INC·Filed 2021·Granted Dec 24, 2024·0 cites·9 claims
- 3061US2010119602A1Phosphate binder with reduced pill burdenSPECTRUM PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3160US11541012B1Compositions comprising disodium levofolinateSPECTRUM PHARMACEUTICALS INC·Filed 2019·Granted Jan 3, 2023·0 cites·15 claims
- 3260US2018280468A1Treatment of primary and metastatic carcinomaSPECTRUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3358US10022421B2Treatment of primary and metastatic carcinomaSPECTRUM PHARMACEUTICALS INC·Filed 2016·Granted Jul 17, 2018·0 cites·11 claims
- 3458US9511091B2Rare earth metal compounds, methods of making, and methods of using the sameSPECTRUM PHARMACEUTICALS INC·Filed 2015·Granted Dec 6, 2016·0 cites·11 claims
- 3558US2020261455A1Inhibitors of mutant family tyrosine-kinasesSPECTRUM PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3658US2007010570A1Medical Compositions for Intravesical Treatment of Bladder CancerSPECTRUM PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 3757US2011123628A1Rare earth metal compounds, methods of making, and methods of using the sameSPECTRUM PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
- 3856US9713616B2Pharmaceutical compositions comprising L-leucovorinSPECTRUM PHARMACEUTICALS INC·Filed 2013·Granted Jul 25, 2017·0 cites·13 claims
- 3955US2010278910A1Rare earth metal compounds, methods of making, and methods of using the sameSPECTRUM PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 4055US2005215615A1Medical compositions for intravesical treatment of bladder cancerSPECTRUM PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4154US2021353627A1Novel quinazoline egfr inhibitorsSPECTRUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4254US2006063788A1Carbon monoxide dependent guanylyl cyclase modifiers and methods of useSPECTRUM PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 4353US2022296598A1Poziotinib Combination with VEGFR2 Inhibitors and Methods of Use ThereofSPECTRUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4453US2021145834A1Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereofSPECTRUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4551US2011251143A1Stable elsamitrucin salt formulationsSPECTRUM PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4651US2014336268A1Formulations of vitamin k analogs for topical useSPECTRUM PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4751US2023027238A1Methods of treatment using g-csf protein complexSPECTRUM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4850US2023277628A1Methods for promoting anti-tumor immune response in a subject in need thereof using encapsulated interleukin 12SPECTRUM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4946US2021260064A1Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereofSPECTRUM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 5044US2007293445A1Stable Elsamitrucin Salts Suitable for Pharmaceutical FormulationsSPECTRUM PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →